TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30282144
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine 1 ml + physiological saline 2 ml (Group C)
Study: 30282144
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline 3 ml (Group D)
Study: 20218984
Drug: Certoparin (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certoparin (3000 U of anti-factor Xa once daily)
Study: 20218984
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (UFH) (5000 IU t.i.d.)
Study: 17485070
Drug: GaA1As laser,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GaA1As laser, lambda=660nm, power of 30mW, energy dose of 2J/cm(2), applied directly and perpendicularly into the cavity in a single visit.
Study: 17485070
Drug: No laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: No laser therapy (control group).
Study: 7695337
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg clavulanic acid with 2,000 mg amoxicillin
Study: 7695337
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg clavulanic acid with 2,000 mg amoxicillin
Study: 7017081
Drug: VM-26 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM-26 (60 mg/sq m on Day 1) plus CCNU (130 mg/sq m on Day 2), repeated every 6 weeks
Study: 29169500
Drug: Heparin-bonded endoluminal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded endoluminal grafts
Study: 26456233
Drug: Twice-weekly resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly resistance training (2× RT)
Study: 26456233
Drug: Once-weekly resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly resistance training (1× RT)
Study: 26456233
Drug: Twice-weekly balance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly balance and tone (BAT)
Study: 19438432
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (n = 30) applied once daily for 6 months
Study: 19438432
Drug: Vehicle (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (n = 30) applied once daily for 6 months
Study: 17554147
Drug: hGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGH treatment (20, 35, or 50 microg/kg per day)
Study: 12657990
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of PGE(1) (20 microg) solution
Study: 12657990
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of saline solution
Study: 12657990
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of dexamethasone (8 mg) solution
Study: 8807140
Drug: Response to
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response to different anti-hypertensive agents
Study: 1860198
Drug: Warfarin (dose-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (dose-adjusted to prolong prothrombin time to 1.3-1.8 times control)
Study: 25904220
Drug: Betahistine 50
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 50 mg
Study: 25904220
Drug: Betahistine 100
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 100 mg
Study: 25904220
Drug: Betahistine 200
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 200 mg
Study: 23973139
Drug: Information on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information on analgesics and non-pharmacological methods for pain relief
Study: 23973139
Drug: Perceptions of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceptions of analgesic use
Study: 8671164
Drug: Standard intracervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intracervical injection
Study: 1754839
Drug: SnF2-amine fluoride
Normalized name: Aminic acid
DrugBank: Formic acid (DB01942)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SnF2-amine fluoride (AmF) combination (F-content 1.20%)
Study: 31714191
Drug: FE2mg (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FE2mg (2 mg/kg)
Study: 31714191
Drug: FE4mg (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: FE4mg (4 mg/kg)
Study: 31171029
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of piperacillin/tazobactam (TZP) guided by daily therapeutic drug monitoring (TDM)
Study: 31171029
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of total daily dose of TZP without TDM guidance (13.5 g TZP in normal renal function)
Study: 31171029
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of TZP guided by daily TDM
Study: 31171029
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of TZP without TDM guidance
Study: 25886918
Drug: Computerized dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized dosing
Study: 25886918
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing
Study: 21412996
Drug: 0.125% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% levobupivacaine (80 ml)
Study: 19663892
Drug: Maribavir 400
Normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maribavir 400 mg p.o. q12 h
Study: 17873811
Drug: Boston brace
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Boston brace treatment
Study: 9190842
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of (S)-gallopamil
Study: 9190842
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of pseudoracemic (RS)-gallopamil
Study: 9190842
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of (R)-gallopamil
Study: 9190842
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of (R)-gallopamil
Study: 3893513
Drug: RS-43179 gel
Normalized name: (RS)-bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS-43179 gel
Study: 3893513
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide (Synalar gel)
Study: 27139158
Drug: Desvenlafaxine 250
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desvenlafaxine 250 mg/d
Study: 15353828
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitor (eptifibatide)
Study: 15353828
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no glycoprotein IIb/IIIa inhibitor)
Study: 8521099
Drug: Natural course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural course (no treatment)
Study: 2232464
Drug: Emoxipin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emoxipin (10 mg/kg intravenously for 5 days, then 1 mg/kg intramuscularly for 15 days)
Study: 19467806
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of dinoprostone gel 0.5mg (Prepidil) every 6 hours (group I)
Study: 19467806
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of dinoprostone gel 0.5mg (Prepidil) every 12 hours (group II)
Study: 8701417
Drug: Indobufen 200
Normalized name: indobufen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen 200 mg b.i.d. for 7 days
Study: 8701417
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg/d for 7 days
Study: 6863645
Drug: Oral Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tetracycline (TCN)
Study: 6863645
Drug: Topical Tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Tetracycline (TCN) preparation
Study: 8858275
Drug: Mefloquine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (250 mg)
Study: 2858743
Drug: Chloroquine (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (450 mg)
Study: 2858743
Drug: Mefloquine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (750 mg)
Study: 2858743
Drug: MSP (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP (750 mg mefloquine plus 3 tablets of 'Fansidar')
Study: 24885076
Drug: Conventional hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional hand therapy
Study: 20968112
Drug: Fenofibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (200 mg once a day)
Study: 12848632
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg once daily)
Study: 1829514
Drug: Oral cephalosporins
Normalized name: Cephalosporium roseum
DrugBank: Cephalosporium roseum (DB10932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cephalosporins
Study: 6357976
Drug: Dolgit Creme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolgit Creme (5% ibuprofen) applied 3 or more times daily (4-10 cm strip)
Study: 31964449
Drug: AMPH EROS
Normalized name: AMPH-b
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMPH EROS 2.5 mg/mL (fasted)
Study: 30912838
Drug: Intramyocardial injections
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injections of 150 million allogeneic mesenchymal precursor cells (MPCs)
Study: 30912838
Drug: Cryoprotective medium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryoprotective medium (sham treatment)
Study: 24255129
Drug: Serelaxin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin (30 µg/kg/day 20‐h infusion and 4‐h post‐infusion period)
Study: 22850511
Drug: VP20621 (10^8
Approvals — FDA: no, EMA: no, PMDA: no
Description: VP20621 (10^8 spores twice a day)
Study: 22850511
Drug: VP20621 (10^4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VP20621 (10^4, 10^6, or 10^8 spores daily) after vancomycin administration
Study: 20492512
Drug: alpha‐tocopherol 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐tocopherol 1000 mg/day (TOCO)
Study: 18606249
Drug: Daily assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily assessment (daily diaries)
Study: 18606249
Drug: Standard weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weekly clinic assessment
Study: 16020959
Drug: Budesonide 3
Normalized name: budesonide 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 3 mg orally 3 times daily
Study: 11120419
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean dose 4.35 +/- 1.7 mg/day)
Study: 11120419
Drug: Olanzapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (mean dose 10.56 +/- 4.9 mg/day)
Study: 11120419
Drug: Haloperidol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (mean dose 10.01 +/- 6.1 mg/day)
Study: 1649874
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of two rotavirus vaccine strains (VP7 serotypes 1 and 2)
Study: 6360401
Drug: Mefloquine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (1000 mg)
Study: 6360401
Drug: Sulfadoxine-pyrimethamine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (1500 mg + 75 mg pyrimethamine)
Study: 29920594
Drug: 0 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 μg/d vitamin D3
Study: 29920594
Drug: 10 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg/d vitamin D3
Study: 29920594
Drug: 20 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg/d vitamin D3
Study: 27628763
Drug: Warfarin (low-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (low-dose, short-term use)
Study: 27628763
Drug: Warfarin (long-term,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (long-term, high-dose use)
Study: 27628763
Drug: Other anticoagulants
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other anticoagulants
Study: 24979398
Drug: AM‐111 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM‐111 0.4 mg/ml
Study: 22024564
Drug: Milk product
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk product enriched with soy isoflavones (50 mg/day)
Study: 19901111
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (docetaxel/doxorubicin/cyclophosphamide (TAC) or two cycles of TAC followed by four cycles of vinorelbine/capecitabine)
Study: 8535552
Drug: Felodipine 10-20
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 10-20 mg daily
Study: 8535552
Drug: Metoprolol 100-200
Normalized name: metoprolol tartrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100-200 mg daily
Study: 8535552
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of felodipine 10-20 mg plus metoprolol 100 mg daily
Study: 2199180
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific medication
Study: 872364
Drug: Pyridine-extracted alum-precipitated
Normalized name: Precipitated Sulfur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridine-extracted alum-precipitated grass pollen vaccine (Alavac P)
Study: 872364
Drug: Glutaraldehyde-modified pollen-tyrosine
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutaraldehyde-modified pollen-tyrosine vaccine (Pollinex)
Study: 28329393
Drug: Tuberculosis treatment
Normalized name: Hydrazides for tuberculosis treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculosis treatment
Study: 28506378
Drug: Pharmacist-led intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led intervention (contacting primary care prescribers by phone and fax to obtain a prescription for an appropriate statin)
Study: 24335848
Drug: candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: candesartan 16 mg
Study: 24335848
Drug: propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol 160 mg
Study: 10613619
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g acetaminophen
Study: 23511692
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g dextrose (placebo)
Study: 19075138
Drug: Dapsone gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone gel, 5% and Vehicle gel
Study: 14599636
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy for severe combined immunodeficiency disorder
Study: 14599636
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy for cystic fibrosis
Study: 14599636
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy for coronary artery disease
Study: 14599636
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy for peripheral arterial disease
Study: 14599636
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy for hemophilia
Study: 14599636
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy (general)
Study: 9188878
Drug: Calcitriol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (3 micrograms/g) ointment
Study: 9188878
Drug: Calcipotriol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol (50 micrograms/g) ointment
Study: 3194074
Drug: Cefoxitin 1
Normalized name: cefoxitin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin 1 g intravenously at induction of anaesthesia
Study: 3194074
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g intravenously at induction of anaesthesia
Study: 24206459
Drug: Bardoxolone methyl
Normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bardoxolone methyl (20 mg daily)
Study: 11172164
Drug: Risedronate (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (2.5 or 5.0 mg daily)
Study: 3918510
Drug: Lentinan in
Normalized name: lentinan
DrugBank: Lentinan (DB13480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentinan in combination with chemotherapeutic agents (5FU + mitomycin C or tegafur)
Study: 3918510
Drug: Lentinan in
Normalized name: lentinan
DrugBank: Lentinan (DB13480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentinan in combination with tegafur for gastric cancer
Study: 3918510
Drug: Lentinan in
Normalized name: lentinan
DrugBank: Lentinan (DB13480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentinan in combination with tegafur for colorectal cancer
Study: 19443680
Drug: Telavancin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin 10 mg/kg + Aztreonam 2 g
Study: 19443680
Drug: Telavancin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin 10 mg/kg + Piperacillin/Tazobactam 4.5 g
Study: 19443680
Drug: Aztreonam 2
Normalized name: aztreonam 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam 2 g
Study: 11270009
Drug: Sevoflurane (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane (0.5 L min‐1 for at least 2 h)
Study: 11270009
Drug: Isoflurane (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane (0.5 L min‐1 for at least 2 h)
Study: 10512080
Drug: Amitriptyline 25-75
Normalized name: amitriptyline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25-75 mg/day
Study: 2376155
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP, 500 micrograms twice daily)
Study: 216235
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oxazepam
Study: 31418140
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg daily for 48 weeks
Study: 27899322
Drug: Ampicillin and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin and/or sulbactam administered 1 hour before ESD and every 8 hours twice more (group 1)
Study: 27899322
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution without antibiotics (group 2)
Study: 26414759
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) plus usual care (UC)
Study: 19826188
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea catechins (GTC) - 670 mg per day (6 capsules)
Study: 19826188
Drug: High dietary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dietary GTC (5 g GTC/kg) in male rats
Study: 19826188
Drug: Lower dietary
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dietary GTC (0, 0.05, 0.5, 1 g GTC/kg) in male rats
Study: 11372037
Drug: TFPI (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFPI (0.2 mg/kg/h after a bolus of 0.05 mg/kg)
Study: 9236484
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (0.5, 1, or 2 g/kg)
Study: 9236484
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (1% albumin)
Study: 21092221
Drug: NVP (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP (5 g) added to cornflakes
Study: 21092221
Drug: NVP (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP (5 g) added to rice
Study: 21092221
Drug: NVP (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP (5 g) added to yogurt
Study: 21092221
Drug: NVP (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP (5 g) added to turkey dinner
Study: 21092221
Drug: NVP (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP (2.5 g) added to granola
Study: 21092221
Drug: NVP (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP (5 g) added to granola
Study: 21092221
Drug: NVP (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP (5 g) added to various foods
Study: 21092221
Drug: NVP (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP (5 g) in general
Study: 18691987
Drug: Rifampicin 450
Normalized name: Rifampicin 450 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 450 mg once daily for 6 days
Study: 15929958
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus as-needed ambulatory oxygen
Study: 15929958
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus ambulatory compressed air
Study: 15929958
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (home oxygen therapy with an oxygen concentrator only)
Study: 12912865
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin (0.006%)
Study: 1744422
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of molsidomine (n = 11)
Study: 1744422
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of molsidomine (n = 8)
Study: 31544382
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (sodium hyaluronate eye drops)